Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing ViraxImmune with the intention of providing an immunology profiling platform that assesses each individualâs immune risk profile against global viral diseases as well as helping with the early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation. Its product portfolio includes ViraxClear and ViraxVet. ViraxClear offers a range of accurate diagnostic testing kits and machines. ViraxVet offers various rapid and molecular tests for small animal veterinary diagnostics. The Company is initially focused on diseases associated with post-viral syndromes, including SARS-CoV-2, Human Papillomavirus (HPV), Malaria, Hepatitis B, and Herpes (HSV-1).
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing ViraxImmune with the intention of providing an immunology profiling platform that assesses each individualâs immune risk profile against global viral diseases as well as helping with the early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation. Its product portfolio includes ViraxClear and ViraxVet. ViraxClear offers a range of accurate diagnostic testing kits and machines. ViraxVet offers various rapid and molecular tests for small animal veterinary diagnostics. The Company is initially focused on diseases associated with post-viral syndromes, including SARS-CoV-2, Human Papillomavirus (HPV), Malaria, Hepatitis B, and Herpes (HSV-1).
äŒæ¥ã³ãŒãVRAX
äŒæ¥åVirax Biolabs Group Ltd
æé«çµå¶è²¬ä»»è ãCEOãFoster (James)
ãŠã§ããµã€ãhttps://www.viraxbiolabs.com
ãããã質å
Virax Biolabs Group LtdïŒVRAXïŒã®çŸåšã®æ ªäŸ¡ã¯ãããã§ããïŒ
î
Virax Biolabs Group LtdïŒVRAXïŒã®çŸåšã®æ ªäŸ¡ã¯0.370ã§ãã
Virax Biolabs Group Ltdã®ãã£ãã«ãŒã·ã³ãã«ã¯äœã§ããïŒ
î
Virax Biolabs Group Ltdã®ãã£ãã«ãŒã·ã³ãã«ã¯VRAXã§ãã
Virax Biolabs Group Ltdã®52é±é«å€ã¯ãããã§ããïŒ
î
Virax Biolabs Group Ltdã®52é±é«å€ã¯3.200ã§ãã
Virax Biolabs Group Ltdã®52é±å®å€ã¯ãããã§ããïŒ
î
Virax Biolabs Group Ltdã®52é±å®å€ã¯0.350ã§ãã
Virax Biolabs Group Ltdã®æäŸ¡ç·é¡ã¯ãããã§ããïŒ
î
Virax Biolabs Group Ltdã®æäŸ¡ç·é¡ã¯2.42Mã§ãã